OKUR — OnKure Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
$3.56
-$0.07 (-1.93%)
OnKure Therapeutics, Inc. (OKUR) is a biotechnology company listed on NASDAQ. It is led by Nicholas A. Saccomano Ph.D., based in 6707 Winchester Circle, Boulder, CO, United States, 80301, with about 46 employees. OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
Net income was -$14.7M. OKUR currently screens at market cap $76.6M and trailing P/E 71.8.
Use this OKUR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OKUR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OKUR SEC filings page. Lician reads the product cache first so this HTML stays unique to OnKure Therapeutics, Inc. even when a live quote feed is slow.
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
OKUR Key Statistics
Market Cap
$76.57M
Volume
116,228
Previous Close
$3.89
Day Range
$3.79 – $4.04
P/E Ratio
71.75
EPS
-$15.28
Revenue
$0.00
Net Income
-$52.67M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
46
OKUR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$52.67M | -$35.31M | -$51.95M |
| EPS (Diluted) | -$15.28 | -$124.41 | -$2.12 |
Total Assets
$114.91M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$110.76M
Operating Cash Flow
-$51.12M
Free Cash Flow
$0.00
OnKure Therapeutics, Inc. Company Information
- President, CEO & Director
- Nicholas A. Saccomano Ph.D.
- Headquarters
- 6707 Winchester Circle, Boulder, CO, United States, 80301
- Website
- onkuretherapeutics.com
- Phone
- 720 307 2892
- IPO / Founded
- 2024-10-07
- Sector
- Healthcare
- Industry
- Biotechnology